Literature DB >> 35294735

Chemokine (C-C motif) ligand 5 (RANTES) concentrations in the peripheral blood of patients with a depressive disorder.

Elżbieta Małujło-Balcerska1,2, Anna Kumor-Kisielewska3, Janusz Szemraj4, Tadeusz Pietras5.   

Abstract

BACKGROUND: Inflammation plays a role in the pathomechanism of depressive disorder. Cytokines interact with iodothyronine deiodinases (DIOs) that are involved in thyroid hormone (TH) metabolism. DIOs are known as modifiers of the inflammatory response. RANTES is a chemokine that has been detected in a wide range of inflammatory disorders, but is less studied in depression. We aimed to investigate the concentration of RANTES in patients with recurrent depressive disorder (rDD) and examine any potential correlation with other molecules, such as interleukins (ILs) and DIOs.
METHODS: The levels of RANTES and other molecules associated with depressive disorder, including deiodinase type 1 (DIO1), interleukin (IL)1β, and IL-6, were measured by enzymatic immune assay (ELISA) in the serum of 43 patients with depressive disorder and 36 controls.
RESULTS: RANTES levels were higher in depressed patients than in controls. The level of RANTES was negatively correlated with the deiodinase type 1 (DIO1) level in women diagnosed with rDD. IL-1β and IL-6 levels were significantly higher in depressed patients than in controls. IL-1β was positively correlated with deiodinase type 3 (DIO3). A negative correlation between DIO1 and the number of depressive episodes in women with rDD was observed.
CONCLUSION: With the observed elevated RANTES levels, increases in ILs concentrations, and a possible link between immune aspects and DIOa in patients with rDD, our study contributes to the current pool of knowledge about the complex aetiology of depression and suggests future studies focus on precision mechanisms that explain the link between TH-related molecules and immune molecules.
© 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.

Entities:  

Keywords:  Deiodinase iodothyronine; Depressive disorder; Inflammation; Interleukins; RANTES

Mesh:

Substances:

Year:  2022        PMID: 35294735     DOI: 10.1007/s43440-022-00360-5

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.919


  39 in total

1.  Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.

Authors:  P C Taylor; A M Peters; E Paleolog; P T Chapman; M J Elliott; R McCloskey; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  2000-01

2.  Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids.

Authors:  M Leech; C Metz; P Hall; P Hutchinson; K Gianis; M Smith; H Weedon; S R Holdsworth; R Bucala; E F Morand
Journal:  Arthritis Rheum       Date:  1999-08

3.  IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells.

Authors:  Simone Magagnin Wajner; Iuri Martin Goemann; Ana Laura Bueno; P Reed Larsen; Ana Luiza Maia
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

Review 4.  Major Depressive Disorder in Medical Illness: A Review of Assessment, Prevalence, and Treatment Options.

Authors:  Robyn Thom; David A Silbersweig; Robert J Boland
Journal:  Psychosom Med       Date:  2019-04       Impact factor: 4.312

Review 5.  The cytokine network in the pathogenesis of major depressive disorder. Close to translation?

Authors:  Maria Cristina Petralia; Emanuela Mazzon; Paolo Fagone; Maria Sofia Basile; Vittorio Lenzo; Maria Catena Quattropani; Santo Di Nuovo; Klaus Bendtzen; Ferdinando Nicoletti
Journal:  Autoimmun Rev       Date:  2020-03-13       Impact factor: 9.754

Review 6.  Platelet-derived chemokines in inflammation and atherosclerosis.

Authors:  Constantinos Bakogiannis; Marco Sachse; Kimon Stamatelopoulos; Konstantinos Stellos
Journal:  Cytokine       Date:  2017-12-01       Impact factor: 3.861

Review 7.  Targeting the CCL2-CCR2 axis in depressive disorders.

Authors:  Katarzyna Curzytek; Monika Leśkiewicz
Journal:  Pharmacol Rep       Date:  2021-05-24       Impact factor: 3.024

Review 8.  Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis.

Authors:  S P Leighton; L Nerurkar; R Krishnadas; C Johnman; G J Graham; J Cavanagh
Journal:  Mol Psychiatry       Date:  2017-11-14       Impact factor: 15.992

Review 9.  Targeting CCL5 in inflammation.

Authors:  Rafael Elias Marques; Rodrigo Guabiraba; Remo Castro Russo; Mauro Martins Teixeira
Journal:  Expert Opin Ther Targets       Date:  2013-10-03       Impact factor: 6.902

Review 10.  Shedding light on the role of CX3CR1 in the pathogenesis of schizophrenia.

Authors:  Katarzyna Chamera; Magdalena Szuster-Głuszczak; Agnieszka Basta-Kaim
Journal:  Pharmacol Rep       Date:  2021-05-22       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.